skip to content
Primary navigation

Veozah™

DrugVeozah™ (fezolinetant) [Astellas Pharma US, Inc.]

January 2025

Therapeutic area

Initial approval criteria

  • Patient is at least 18 years of age; AND
  • Patient has a diagnosis of menopause with moderate to severe vasomotor symptoms; AND
  • Patient does not have cirrhosis; AND
  • Patient does not have severe renal impairment or end-stage renal disease; AND
  • Patient will avoid concomitant therapy with weak, moderate, or strong CYP1A2 inhibitors (e.g., fluvoxamine, mexiletine, cimetidine); AND
  • Prescriber attests that baseline liver function tests have been conducted and total bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels are not elevated ≥ 2 times the upper limit of normal (ULN); AND
  • Initial approval is for 3 months

Renewal criteria

  • Patient must continue to meet the above criteria; AND
  • Patient must have symptom improvement; AND
  • Patient has not experienced any treatment-restricting adverse effects (e.g., ALT or AST > 3 times the ULN).
  • Renewal approval is for 12 months

Quantity limits

  • 34 tablets per 34 days

Questions?

Provider Call Center (844) 575-7887

back to top